{"id":"W4383982112","doi":"10.1016/s1470-2045(23)00276-0","title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"Merck Sharp and Dohme; National Cancer Institute; Eisai","keywords":"Lenvatinib; Pembrolizumab; Medicine; Renal cell carcinoma; Internal medicine; Clinical endpoint; Population; Oncology; Adverse effect; Phases of clinical research; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001869901,0.001804145,0.00282745,0.0003610757,0.000374494,0.001333712,0.0008666522,0.001506602,0.005962691],"category_scores_gemma":[0.001236512,0.0005573892,0.002069576,0.0004190744,0.0008384167,0.00143559,0.0004476799,0.004693447,0.001394672],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001079205,"about_ca_system_score_gemma":0.001254136,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001155664,"about_ca_topic_score_gemma":0.003152205,"domain_scores_codex":[0.999525,0.0002158825,0.0000168263,0.0001000253,0.00003670211,0.0001056813],"domain_scores_gemma":[0.9994153,0.0001272739,0.0001069255,0.00004852262,0.00003390947,0.0002680996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9025803,0.01142311,0.0009864209,0.00153833,0.002242878,0.00008888327,0.0001268472,0.001499318,0.005744468,0.0003366959,0.004978302,0.06845462],"study_design_scores_gemma":[0.9293647,0.06537043,0.002183988,0.00004715247,0.0004876702,0.00008529223,0.00003057403,0.0005308338,0.0003686652,0.0002519182,0.001262028,0.00001662655],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9771236,0.01095597,0.0007813377,0.001766931,0.0007608303,0.002310217,0.001980355,0.000227955,0.004092818],"genre_scores_gemma":[0.9775688,0.006788195,0.00185834,0.002497628,0.0003991183,0.002007344,0.002663857,0.00005213699,0.006164558],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005962691,"threshold_uncertainty_score":0.01994723,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09302847659005466,"score_gpt":0.3660065527882697,"score_spread":0.2729780761982151,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}